{"id":"NCT00408993","sponsor":"Eli Lilly and Company","briefTitle":"Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China","officialTitle":"Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2006-12-08","resultsPosted":"2009-06-02","lastUpdate":"2011-07-26"},"enrollment":215,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathies"],"interventions":[{"type":"DRUG","name":"Duloxetine Hydrochloride","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.","primaryOutcome":{"measure":"Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Duloxetine","deltaMin":-2.69,"sd":0.19},{"arm":"Placebo","deltaMin":-2.31,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.617"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":["21163113"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Nausea","Dizziness","Somnolence","Constipation","Therapeutic response unexpected"]}}